» Authors » Steven A Grover

Steven A Grover

Explore the profile of Steven A Grover including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 727
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee T, Morris A, Grover S, Murthy S, McDonald E
Open Forum Infect Dis . 2022 Feb; 9(3):ofac008. PMID: 35165657
Background: Several outpatient coronavirus disease 2019 (COVID-19) therapies have reduced hospitalization in randomized controlled trials. The choice of therapy may depend on drug efficacy, toxicity, pricing, availability, and available infrastructure....
2.
Pearson G, Thanassoulis G, Anderson T, Barry A, Couture P, Dayan N, et al.
Can J Cardiol . 2021 Mar; 37(8):1129-1150. PMID: 33781847
The 2021 guidelines primary panel selected clinically relevant questions and produced updated recommendations, on the basis of important new findings that have emerged since the 2016 guidelines. In patients with...
3.
Grover S, Jekki H, Kaouache M, Lowensteyn I
Can J Cardiol . 2021 Feb; 37(5):786-789. PMID: 33640433
Cardiovascular risk assessment has been shown to improve physicians' and patients' understanding of an individual's future risk of cardiovascular disease (CVD). It has also been shown to improve the management...
4.
Lowensteyn I, Berberian V, Berger C, Da Costa D, Joseph L, Grover S
Am J Health Promot . 2019 Jan; 33(6):850-858. PMID: 30665309
Purpose: To evaluate the results of a workplace wellness program that incorporates gamification principles. Design: In this prospective cohort study, the participation rate and observed health outcomes were evaluated after...
5.
Gladstone R, Pudwell J, Nerenberg K, Grover S, Smith G
J Obstet Gynaecol Can . 2019 Jan; 41(8):1157-1167.e1. PMID: 30655227
Objective: Hypertensive disorders of pregnancy (HDP) comprise an independent, sex-specific risk factor for cardiovascular disease (CVD) in women. This study examined the utility of CVD risk models proposed in the...
6.
Lee T, Kaouache M, Grover S
CMAJ Open . 2018 Apr; 6(2):E162-E167. PMID: 29622685
Background: Evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, has been shown to reduce low-density lipoprotein levels by up to 60%. Despite the absence of a reduction in overall...
7.
Lowensteyn I, Berberian V, Belisle P, DaCosta D, Joseph L, Grover S
J Occup Environ Med . 2017 Dec; 60(3):211-216. PMID: 29200188
Objective: The aim of this study was to evaluate the impact of an employee wellness program in Canada. Methods: A comprehensive program including web-based lifestyle challenges was evaluated with annual...
8.
Grover S, Kaouache M, Rempel P, Joseph L, Dawes M, Lau D, et al.
Lancet Diabetes Endocrinol . 2014 Dec; 3(2):114-22. PMID: 25483220
Background: Despite the increased risk of cardiovascular disease and type 2 diabetes associated with excess bodyweight, development of a clinically meaningful metric for health professionals remains a challenge. We estimated...
9.
Banack H, Holly C, Lowensteyn I, Masse L, Marchand S, Grover S, et al.
J Cardiopulm Rehabil Prev . 2014 Apr; 34(3):188-94. PMID: 24681969
Purpose: Recent guidelines from the Canadian Association of Cardiac Rehabilitation highlight the importance of addressing sleep disturbance among participants of cardiac rehabilitation (CR) programs. The primary objective of this study...
10.
Lavoie-Tremblay M, Sounan C, Martin K, Trudel J, Lavigne G, Grover S, et al.
Health Care Manag (Frederick) . 2014 Jan; 33(1):82-90. PMID: 24463595
This study investigated whether the positive behavioral and anthropometric outcomes of a pedometer-based physical activity 8-week challenge were maintained 6 months after the end of the program. It further investigated...